Author:
Pro Barbara,Leber Brian,Smith Mitchell,Fayad Luis,Romaguera Jorge,Hagemeister Fredrick,Rodriguez Alma,McLaughlin Peter,Samaniego Felipe,Zwiebel James,Lopez Adriana,Kwak Larry,Younes Anas
Reference14 articles.
1. Bcl-2 antisense (Genasense) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells;Auer;Blood,2001
2. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999
3. Oblimersen sodium (G3139) sensitizes malignant B-cells to alemtuzumab induced apoptosis;Cotter;Journal of Clinical Oncology,2003
4. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment;Davis;Journal of Clinical Oncology,2000
5. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma;Gascoyne;Blood,1997
Cited by
90 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A case of co‐occurring acute myeloid leukemia and relapsed diffuse large B‐cell lymphoma in a young adult with Shwachman–Diamond syndrome;Pediatric Blood & Cancer;2024-06-04
2. Spleen-targeted delivery systems and strategies for spleen-related diseases;Journal of Controlled Release;2024-06
3. Immune-based therapies in diffuse large B-cell lymphoma;Expert Opinion on Investigational Drugs;2023-06-03
4. Clinical Experience with Pro‐Apoptotic Agents;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15
5. Pharmacologic Features of Drugs Targeting
BCL
2 Family Members;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15